Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Talking Face to Face is Better than a Phone Call

Author(s): Laurent Metzinger* and Valérie Metzinger-Le Meuth

Volume 18, Issue 3, 2020

Page: [302 - 303] Pages: 2

DOI: 10.2174/1570161117999190820150930

« Previous
[1]
Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 2017; 38(41): 3070-8.
[http://dx.doi.org/10.1093/eurheartj/ehx175] [PMID: 28510646]
[2]
Czarny MJ, Nathan AS, Yeh RW, Mauri L. Adherence to dual antiplatelet therapy after coronary stenting: a systematic review. Clin Cardiol 2014; 37(8): 505-13.
[http://dx.doi.org/10.1002/clc.22289] [PMID: 24797884]
[3]
Zeymer U, Cully M, Hochadel M. Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry. Eur Heart J Cardiovasc Pharmacother 2018; 4(4): 205-10.
[http://dx.doi.org/10.1093/ehjcvp/pvy018] [PMID: 29878086]
[4]
Crisci M, Gragnano F, Di Maio M, et al. Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial. Curr Vasc Pharmacol 2020; 18: 298-01.
[http://dx.doi.org/10.2174/1570161117666190524123225] [PMID: 31124422]
[5]
Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005; 3(8): 1597-602.
[http://dx.doi.org/10.1111/j.1538-7836.2005.01380.x] [PMID: 16102024]
[6]
Lordkipanidzé M, So D, Tanguay J-F. Platelet function testing as a biomarker for efficacy of antiplatelet drugs. Biomarkers Med 2016; 10: 903-18.
[http://dx.doi.org/10.2217/bmm-2016-0070]
[7]
Smadja DM, Bura A, Szymezak J, et al. Effect of clopidogrel on circulating biomarkers of angiogenesis and endothelial activation. J Cardiol 2012; 59(1): 30-5.
[http://dx.doi.org/10.1016/j.jjcc.2011.09.002] [PMID: 22100059 ]
[8]
Maitrias P, Metzinger-Le Meuth V, Nader J, et al. the involvement of mirna in carotid-related stroke. Arterioscler Thromb Vasc Biol 2017; 37: 1608-17.
[http://dx.doi.org/10.1161/ATVBAHA.117.309233]
[9]
Tang Q, Lei H, Wu H, et al. Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy. Acta Pharmacol Sin 2019; 40: 208-15.
[http://dx.doi.org/10.1038/s41401-018-0041-7]
[10]
de Boer HC, van Solingen C, Prins J, et al. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J 2013; 34(44): 3451-7.
[http://dx.doi.org/10.1093/eurheartj/eht007] [PMID: 23386708]
[11]
Fourdinier O, Schepers E, Metzinger-Le Meuth V, et al. Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. Sci Rep 2019; 9(1): 4477.
[http://dx.doi.org/10.1038/s41598-019-41101-8] [PMID: 30872798]

Rights & Permissions Print Cite
Article Metrics
14
3
© 2024 Bentham Science Publishers | Privacy Policy